Custom CRISPR sgRNA Lentiviral Vectors & Viruses
Use abm’s All-in-One lentivectors and lentiviruses that express spCas9 along with the sgRNA to simplify the delivery of CRISPR/Cas9 technology right into the target cell. Alternatively, custom sgRNA lentivectors and lentiviruses can be used to deliver sgRNAs into cells that already express the spCas9 nuclease, and thus recruit spCas9 to the target gene (Check out abm’s Cas9-Expressing Stable Cell Lines).
|AAV Vector||Lentivector||Non-Viral Vector||Adenovirus|
|sgRNA for spCas9||Available||Available||Available||Available|
|sgRNA for saCas9||Available||-||-||-|
|All-In-One with spCas9||-||Available||Available||-|
|All-In-One with saCas9||Available||-||-||-|
Lentiviruses can infect both dividing and non-dividing cells in vitro and in vivo, and will integrate stably into the host cell genome, ensuring long-term expression of the construct even in cells that are difficult to infect. Lentivectors, on the other hand, allow transient expression and can be diluted out.
We can design sgRNAs for gene knockouts with spCas9 Nuclease, for promoter activation with dCas9-SAM, for promoter repression with dCas9-KRAB, or for transgenic knock-ins of Custom HDR Templates.
"I have used abm's All-in-One lentiviral system to knockout human IL11, which worked really well. Our labmate also ordered the same system from abm to knockout mouse Axl, and she got good results, too. Thus, we want to stick to the same system."Dr. Ejung Moon, Stanford University, CRISPR
|Service Name||Vector||Quantity||Cat. No.||Price|
|Custom CRISPR sgRNA Lentiviral Vector (for spCas9) – single target||pLenti-U6-sgRNA-PGK-Neo||1.0 μg||C437||$95.00|
|Custom CRISPR sgRNA Lentiviral Vector (for spCas9) – set of three targets||pLenti-U6-sgRNA-PGK-Neo||3 x 1.0 μg||C441||$250.00|
|Custom CRISPR All-in-One Lentiviral Vector (with spCas9) – single target||pLenti-U6-sgRNA-SFFV-Cas9-2A-Puro||1.0 μg||C438||$105.00|
|Custom CRISPR All-in-One Lentiviral Vector(with spCas9) – set of three targets||pLenti-U6-sgRNA-SFFV-Cas9-2A-Puro||3 x 1.0 μg||C442||$280.00|
|Packaging Service - Standard||Size||Titer||CAT. NO.||PRICE|
|Custom CRISPR Lentivirus Packaging – single target||300 μl||107 IU/ml||C445||$420.00|
|Custom CRISPR Lentivirus Packaging – three targets, individually packaged||3 x 300 μl||107 IU/ml||C447||$940.00|
|Custom CRISPR Lentivirus Packaging – three targets, pooled packaging||300 μl||107 IU/ml||C448||$420.00|
*For additional titer or volume options, please inquire.
|What promoter(s) do your sgRNA and All-in-One lentivectors have?|
sgRNAs are expressed from the U6 promoter and All-in-One lentivectors and lentiviruses express Cas9 from the SFFV promoter.
|What is the approximate time frame to generate CRISPR lentiviral constructs?|
The typical lead time is around 1-3 weeks for CRISPR lentivectors and 4-6 weeks for lentiviruses. Please inquire for a more accurate lead time.
|How should I store my lentivirus?|
Aliquots should be made for the lentivirus and stored at -70 degrees Celsius.
|If a high-titer custom lentivirus was ordered, do you do the lentiviral titration after a freeze-thaw or straight after production before the freeze-down step?|
We do the titration after aliquoting and freeze-down. Thus, the titer should be accurate for the customer after they thaw the finished product for the first time.
|Which virus has your lentivirus expression system been derived from? Is it HIV?|
Our lentivirus expression system is derived from Human HIV-1 Virus. It employs third generation self-inactivating recombinant lentiviral vectors with enhanced biosafety features and minimal relation to wild-type Human HIV-1 Virus.
|How do you verify the titer?|
We use our LV900 series - qPCR Lentivirus Titration(Titer) Kit. This kit quantifies a proprietary region of the lentiviral 5’-LTR.
|What is the packaging capacity for Lentivirus?|
The maximum insert size is <9 kb between the 5'LTR to 3'LTR.
|01||Kang, Y. J. et al. "Regulation of NKT cell-mediated immune responses to tumours and liver inflammation by mitochondrial PGAM5-Drp1 signalling." Nat. Commun. (2015) 6:8371 doi: 10.1038/ncomms9371|
|02||Jiang, G. et al. "Isorhapontigenin (ISO) inhibits invasive bladder cancer (BC) formation in vivo and human BC invasion in vitro by targeting STAT1/FOXO1 Axis." Cancer Prev Res. Published Online First April 14, 2016.doi: 10.1158/1940-6207.CAPR-15-0338|
|03||Okugawa, Y. et al. "Clinical significance of SNORA42 as an oncogene and a prognostic biomarker in colorectal cancer." Gut (2015)doi:10.1136/gutjnl-2015-309359|